The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Uric Acid and Long-term Outcomes in CKD
Open accessAbstract
Background Hyperuricemia is prevalent in chronic kidney disease (CKD); however data are limited on the relationship of uric acid levels with long term outcomes in this patient population. Study Design Cohort Study Setting & Participants The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial (N=840), conducted 1989–1993, to examine the effects of strict blood pressure control and dietary protein restriction on progression of stage 3–4 CKD. This analysis included 838 patients. Predictor Uric acid Outcomes & Measurements The study evaluated the association of baseline uric acid levels with all-cause mortality, cardiovascular (CVD) mortality, and kidney failure. Results Mean (SD) age was 52 (12) years, glomerular filtration rate was 33 (12) ml/min/1.73m2, and uric acid was 7.63 (1.66) mg/dl. During a median follow-up of 10 years, 208 (25%) participants died of any cause, 127 (15%) from CVD, and 553 (66%) reached kidney failure. In multivariate models, the highest tertile of uric acid was associated with increased risk of all-cause (HR, 1.57 [95% CI, 1.07–2.32]) mortality, a trend towards CVD mortality (HR, 1.47 [95% CI, 0.90–2.39]) and no association with kidney failure (HR, 1.20 [95% CI, 0.95–1.51), compared to the lowest tertile. In continuous analyses, a 1-mg/dl higher uric acid was associated with 17% increased risk of all-cause (HR, 1.17 [95% CI, 1.05–1.30]), and 16% increased risk of CVD mortality (HR, 1.16 [95% CI, 1.01–1.33]), but was not associated with kidney failure (HR, 1.02 [95% CI, 0.97–1.07]). Limitations Primary analyses were based on single measurement of uric acid. The results are primarily generalizable to relatively young white patients with predominantly non-diabetic CKD. Conclusions In stage 3–4 CKD, hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality but not kidney failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Self-citationSerum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992
Fang, J., & Alderman, M. H. (2000) · JAMA · doi:10.1001/jama.283.18.2404 · Cited by 1,513
Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?
Johnson, R. J., Kang, D.-H., Feig, D., Kivlighn, S., Kanellis, J., Watanabe, S., Tuttle, K. R., Rodriguez-Iturbe, B., Herrera-Acosta, J., & Mazzali, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000069700.62727.c5 · Cited by 1,361
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-1-199907060-00003 · Cited by 1,282
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort
Iseki, K., Ikemiya, Y., Inoue, T., Iseki, C., Kinjo, K., & Takishita, S. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)00934-5 · Cited by 526
Sarnak, M. J., Greene, T., Wang, X., Beck, G., Kusek, J. W., Collins, A. J., & Levey, A. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00009 · Cited by 521
Self-citationUric Acid and Incident Kidney Disease in the Community
Weiner, D. E., Tighiouart, H., Elsayed, E. F., Griffith, J. L., Salem, D. N., & Levey, A. S. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101075 · Cited by 462
Self-citationRelationship of Uric Acid With Progression of Kidney Disease
Chonchol, M., Shlipak, M. G., Katz, R., Sarnak, M. J., Newman, A. B., Siscovick, D. S., Kestenbaum, B., Carney, J. K., & Fried, L. F. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.05.013 · Cited by 420
Self-citationRao, G. N., Corson, M. A., & Berk, B. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)93017-6 · Cited by 391
Cited by
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Uric acid and chronic kidney disease: which is chasing which?
Johnson, R. J., Nakagawa, T., Jalal, D., Sanchez-Lozada, L. G., Kang, D.-H., & Ritz, E. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft029 · Cited by 654
Effects of Allopurinol on the Progression of Chronic Kidney Disease
Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915833 · Cited by 473
Soluble Uric Acid Activates the NLRP3 Inflammasome
Braga, T. T., Forni, M. F., Correa-Costa, M., Ramos, R. N., Barbuto, J. A., Branco, P., Castoldi, A., Hiyane, M. I., Davanso, M. R., Latz, E., et al. (2017) · Scientific Reports · doi:10.1038/srep39884 · Cited by 440
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.028 · Cited by 383
Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease
Podkowińska, A., & Formanowicz, D. (2020) · Antioxidants · doi:10.3390/antiox9080752 · Cited by 356
URic Acid and Risk Of Heart Failure: A Systematic Review and Meta-Analysis
Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H., Jing, X., Chen, J., & Wang, J. (2014) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft132 · Cited by 339
Physiology of Hyperuricemia and Urate-Lowering Treatments
Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00160 · Cited by 319
Sircar, D., Chatterjee, S., Waikhom, R., Golay, V., Raychaudhury, A., Chatterjee, S., & Pandey, R. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.05.017 · Cited by 314
Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD
Srivastava, A., Kaze, A. D., McMullan, C. J., Isakova, T., & Waikar, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.08.017 · Cited by 306
Goicoechea, M., Garcia de Vinuesa, S., Verdalles, U., Verde, E., Macias, N., Santos, A., Pérez de Jose, A., Cedeño, S., Linares, T., & Luño, J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.016 · Cited by 302
Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., Negri, C., & Bonora, E. (2012) · Diabetes Care · doi:10.2337/dc11-1346 · Cited by 274
Soltani, Z., Rasheed, K., Kapusta, D. R., & Reisin, E. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0344-5 · Cited by 272
Uric Acid as a Target of Therapy in CKD
Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.021 · Cited by 268
Association of Uric Acid With Change in Kidney Function in Healthy Normotensive Individuals
Bellomo, G., Venanzi, S., Verdura, C., Saronio, P., Esposito, A., & Timio, M. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.01.019 · Cited by 260
Dietary Antioxidant Supplements and Uric Acid in Chronic Kidney Disease: A Review
Roumeliotis, S., Roumeliotis, A., Dounousi, E., Eleftheriadis, T., & Liakopoulos, V. (2019) · Nutrients · doi:10.3390/nu11081911 · Cited by 149
Low protein diets for non-diabetic adults with chronic kidney disease
Hahn, D., Hodson, E. M., & Fouque, D. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001892.pub4 · Cited by 128
Metadata
- Authors
- Madero, M., Sarnak, M. J., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Menon, V.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2009-05
- Volume
- 53
- Issue
- 5
- Pages
- 796-803
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2012967253
- Cited by
- 436
- References
- 31
- FWCI
- 15.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.